Anti-ATP13A2 antibody produced in rabbit
SIGMA/A9607 - ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
Synonym: Anti-ATPase type 13A2; Anti-PARK9
Product Type: Chemical
Enhanced Validation-By Recombinant Expression Antibody recognition: Anti-ATP13A2 antibody produced in Rabbit (Cat. No. A9607) is confirmed by western blot in the cell sample that has been altered to overexpress the target protein-HEK-293T over expressing ATP13A2 (Lane 1) while no staining is detected in the wild type sample-HEK-293T (Lane 2). The antibody was developed with Goat Anti-Rabbit IgG, Peroxidase conjugate (Cat. No. A0545) and a chemiluminescent substrate. Antibody dilution: 1.5 μg/mL.
Immunoblotting Cell and tissue lysates were separated on SDS-PAGE, probed with 1.5 μg/mL Anti-ATP13A2 (Cat. No. A9607) and developed using Goat Anti-Rabbit IgG-Peroxidase (Cat. No. A0545) and a chemiluminescent substrate. Lanes 1. Mouse brain extract (cytosolic S1 fraction) 2. HEK-293T overexpressing human ATP13A2 3. HEK-293T untransfected 4. Mouse brain extract (cytosolic S1 fraction). Antibody + ATP13A2 immunizing peptide (human, 195-213)
| antibody form | affinity isolated antibody |
| antibody product type | primary antibodies |
| biological source | rabbit |
| clone | polyclonal |
| concentration | ~1 mg/mL |
| conjugate | unconjugated |
| enhanced validation | recombinant expression Learn more about Antibody Enhanced Validation  |
| form | buffered aqueous solution |
| mol wt | antigen ~129 kDa |
| Quality Level | 200 |
| shipped in | dry ice |
| species reactivity | mouse, human |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | western blot: 1-2 μg/mL using mouse brain extract (S1 fraction) |
| western blot: 2-4 μg/mL using extract of HEk-293T cells expressing human ATP13A2 |
| Application: | Rabbit Anti-ATP13A2 antibody has been used for western blot assays. |
| Biochem/physiol Actions: | Mutations in the gene encoding ATPase type 13A2 (ATP13A2) is implicated with a hereditary form of PD associated with dementia, known as Kufor-Rakeb syndrome (KRS). ATP13A2 shows elevated expression levels in brains of sporadic PD patients, suggesting a potential role in the more common forms of Parkinson′s disease. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| General description: | ATP13A2 is a member of the P5 family of ATPases which function in the transport of inorganic cations. |
| General description: | ATPase type 13A2 (ATP13A2) is a neuronal P-type ATPAse. The gene is also referref as PARK9 (Parkinson′s disease 9). |
| General description: | Rabbit Anti-ATP13A2 antibody binds to human and mouse ATP13A2. |
| Other Notes: | 2024 CiteAb Award Winner for Supplier Succeeding in Parkinson′s Research  |
| Physical form: | Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide. |
| RIDADR | NONH for all modes of transport |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |